All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Visual abstract | Ibrutinib + venetoclax in untreated WM
The Lymphoma Hub is please to present a visual abstract summarizing results from a phase II trial (NCT04273139) assessing the safety and efficacy of ibrutinib, a Bruton’s tyrosine-kinase inhibitor, in combination with venetoclax, a B-cell lymphoma 2 inhibitor, for the treatment of treatment-naïve patients with Waldenstrom macroglobulinemia. Results were published by Castillo et al.1 in Blood.
Although ibrutinib plus venetoclax was associated with a good response rate, there was a higher than expected rate of ventricular arrhythmia, leading to the early termination of the study.1
- Castillo JJ, Branagan AR, Sermer D, et al. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia. 2024;143(7);582-591. DOI:10.1182/blood.2023022420
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
6 votes - 53 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox